Literature DB >> 21442684

Long term patterns of use after initiation of oral antidiabetic drug therapy.

Egbert J F Lamberts1, Giel Nijpels, Laura M C Welschen, Jacqueline G Hugtenburg, Jacqueline M Dekker, Patrick C Souverein, Marcel L Bouvy.   

Abstract

BACKGROUND: The benefits of intensive and continuous antihyperglycemic drug therapy have been extensively described. Data on long-term patterns and modifications of antihyperglycemic drug use are scarce however. Moreover randomized controlled studies may not reflect actual drug use in daily clinical practice.
OBJECTIVE: The aim of this study is to describe the longitudinal patterns of antidiabetic drug modifications after initiation of oral antidiabetic therapy in a large cohort of type 2 diabetes patients. The study will focus specifically on differences between patients who initiate treatment with metformin compared to patients who initiate treatment with sulfonylureas.
METHODS: An observational study of longitudinal patterns of use and modification of oral antidiabetic drug therapy in 3323 patients who started with oral antidiabetic treatment between 1999 and 2007. Drug dispensing data were extracted from pharmacy information systems.
RESULTS: This study shows that changes in international guidelines recommending metformin as first choice initial drug therapy in all patients were rapidly followed by prescribers. Patients starting diabetes treatment with metformin showed fewer modifications to treatment compared to patients initiating treatment with sulfonylureas. After correction for duration of follow-up, Cox regression analysis showed a hazard ratio of 0.84 for any modification in the metformin group compared to the sulfonylureas group.
CONCLUSIONS: This study shows that adherence to type 2 diabetes treatment guidelines for initial treatment is implemented on a large scale. Longitudinal patterns show that the majority of patients receive a small number of modifications to their drug regimen. Discontinuation rates were relatively low.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21442684     DOI: 10.1002/pds.2089

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  6 in total

1.  Initial therapy, persistence and regimen change in a cohort of newly treated type 2 diabetes patients.

Authors:  Ronan T Grimes; Kathleen Bennett; Lesley Tilson; Cara Usher; Susan M Smith; Martin C Henman
Journal:  Br J Clin Pharmacol       Date:  2015-06       Impact factor: 4.335

2.  Patterns of Adherence to Oral Hypoglycemic Agents and Glucose Control among Primary Care Patients with Type 2 Diabetes.

Authors:  Heather F de Vries McClintock; Knashawn H Morales; Dylan S Small; Hillary R Bogner
Journal:  Behav Med       Date:  2014-10-10       Impact factor: 3.104

3.  Long-Term Patterns of Antidiabetic Medication Use in Patients with Type 2 Diabetes.

Authors:  Yang Xu; Zhirong Yang; Hongbo Lin; Peng Shen; Haining Wang; Siyan Zhan
Journal:  Med Sci Monit       Date:  2018-12-02

4.  Durability of initial antidiabetic monotherapy and subsequent treatment adjustment patterns among newly treated type 2 diabetes patients.

Authors:  Yoojin Noh; Sukhyang Lee; Sooyoung Shin
Journal:  Ther Clin Risk Manag       Date:  2018-09-03       Impact factor: 2.423

5.  Treatment Patterns of Diabetes in Italy: A Population-Based Study.

Authors:  Aida Moreno Juste; Enrica Menditto; Valentina Orlando; Valeria Marina Monetti; Antonio Gimeno Miguel; Francisca González Rubio; María Mercedes Aza-Pascual-Salcedo; Caitriona Cahir; Alexandra Prados Torres; Gabriele Riccardi
Journal:  Front Pharmacol       Date:  2019-08-06       Impact factor: 5.810

6.  Antihyperglycaemic treatment patterns, observed glycaemic control and determinants of treatment change among patients with type 2 diabetes in the United Kingdom primary care: a retrospective cohort study.

Authors:  Andrew Maguire; Beth D Mitchell; Javier Cid Ruzafa
Journal:  BMC Endocr Disord       Date:  2014-08-27       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.